IL162929A0 - Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization - Google Patents
Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallizationInfo
- Publication number
- IL162929A0 IL162929A0 IL16292903A IL16292903A IL162929A0 IL 162929 A0 IL162929 A0 IL 162929A0 IL 16292903 A IL16292903 A IL 16292903A IL 16292903 A IL16292903 A IL 16292903A IL 162929 A0 IL162929 A0 IL 162929A0
- Authority
- IL
- Israel
- Prior art keywords
- lasofoxifene
- recrystallization
- purification
- purified
- racemic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36887202P | 2002-03-28 | 2002-03-28 | |
| PCT/IB2003/001033 WO2003082814A1 (en) | 2002-03-28 | 2003-03-17 | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162929A0 true IL162929A0 (en) | 2005-11-20 |
Family
ID=28675551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16292903A IL162929A0 (en) | 2002-03-28 | 2003-03-17 | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
| IL162929A IL162929A (en) | 2002-03-28 | 2004-07-08 | Methods of purifying sophisticated sufoxifen by reconstitution |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162929A IL162929A (en) | 2002-03-28 | 2004-07-08 | Methods of purifying sophisticated sufoxifen by reconstitution |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6906202B2 (xx) |
| EP (1) | EP1487790B1 (xx) |
| JP (1) | JP4268055B2 (xx) |
| KR (1) | KR100636953B1 (xx) |
| CN (1) | CN1283625C (xx) |
| AR (1) | AR039152A1 (xx) |
| AT (1) | ATE459599T1 (xx) |
| AU (1) | AU2003209603B2 (xx) |
| BR (1) | BR0308758A (xx) |
| CA (1) | CA2479924C (xx) |
| DE (1) | DE60331527D1 (xx) |
| DK (1) | DK1487790T3 (xx) |
| ES (1) | ES2339936T3 (xx) |
| HK (1) | HK1073111A1 (xx) |
| HU (1) | HUP0500025A3 (xx) |
| IL (2) | IL162929A0 (xx) |
| MX (1) | MXPA04009259A (xx) |
| PL (1) | PL372727A1 (xx) |
| RS (1) | RS80604A (xx) |
| RU (1) | RU2278861C2 (xx) |
| TW (1) | TW200306974A (xx) |
| WO (1) | WO2003082814A1 (xx) |
| ZA (1) | ZA200405209B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0500025A3 (en) * | 2002-03-28 | 2005-10-28 | Pfizer Prod Inc | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
| CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
| RU2019114079A (ru) | 2016-10-11 | 2020-11-13 | Дьюк Юниверсити | Лечение er+ рака молочной железы лазофоксифеном |
| WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
| KR102412089B1 (ko) | 2021-09-13 | 2022-06-22 | 주식회사 세라수 | Dmts의 정제방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5326865A (en) * | 1990-06-08 | 1994-07-05 | Hercules Incorporated | Arylazo and poly(arylazo) dyes having at least one core radical selected from naphthyl or anthracyl and having at least one 2,3-dihydro-1,3-dialkyl perimidine substituent |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| EP0756205A3 (en) * | 1995-07-26 | 1998-10-14 | Eastman Kodak Company | Pattern transfer techniques for fabrication of lenslet arrays using specialized polyesters |
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| US6180375B1 (en) | 1999-08-27 | 2001-01-30 | Pfizer Inc. | Microbial biotransformation |
| CZ20032959A3 (cs) | 2001-05-01 | 2004-01-14 | Pfizer Products Inc. | Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva |
| HUP0500025A3 (en) * | 2002-03-28 | 2005-10-28 | Pfizer Prod Inc | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
-
2003
- 2003-03-17 HU HU0500025A patent/HUP0500025A3/hu unknown
- 2003-03-17 WO PCT/IB2003/001033 patent/WO2003082814A1/en not_active Application Discontinuation
- 2003-03-17 DE DE60331527T patent/DE60331527D1/de not_active Expired - Lifetime
- 2003-03-17 RS YUP-806/04A patent/RS80604A/sr unknown
- 2003-03-17 BR BR0308758-1A patent/BR0308758A/pt not_active IP Right Cessation
- 2003-03-17 MX MXPA04009259A patent/MXPA04009259A/es active IP Right Grant
- 2003-03-17 RU RU2004128931/04A patent/RU2278861C2/ru not_active IP Right Cessation
- 2003-03-17 ES ES03745203T patent/ES2339936T3/es not_active Expired - Lifetime
- 2003-03-17 CA CA002479924A patent/CA2479924C/en not_active Expired - Fee Related
- 2003-03-17 JP JP2003580282A patent/JP4268055B2/ja not_active Expired - Fee Related
- 2003-03-17 IL IL16292903A patent/IL162929A0/xx unknown
- 2003-03-17 AU AU2003209603A patent/AU2003209603B2/en not_active Ceased
- 2003-03-17 EP EP03745203A patent/EP1487790B1/en not_active Expired - Lifetime
- 2003-03-17 DK DK03745203.4T patent/DK1487790T3/da active
- 2003-03-17 KR KR1020047015249A patent/KR100636953B1/ko active IP Right Grant
- 2003-03-17 AT AT03745203T patent/ATE459599T1/de not_active IP Right Cessation
- 2003-03-17 PL PL03372727A patent/PL372727A1/xx not_active Application Discontinuation
- 2003-03-17 CN CNB038031175A patent/CN1283625C/zh not_active Expired - Lifetime
- 2003-03-26 US US10/397,654 patent/US6906202B2/en not_active Expired - Lifetime
- 2003-03-26 AR ARP030101058A patent/AR039152A1/es unknown
- 2003-03-27 TW TW092106928A patent/TW200306974A/zh unknown
-
2004
- 2004-06-30 ZA ZA2004/05209A patent/ZA200405209B/en unknown
- 2004-07-08 IL IL162929A patent/IL162929A/en active IP Right Grant
-
2005
- 2005-03-28 US US11/092,240 patent/US7358374B2/en active Active
- 2005-07-11 HK HK05105808A patent/HK1073111A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1158223A1 (en) | Purification of anti-her2 antibodies -2 (her-2) | |
| HK1073111A1 (en) | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization | |
| AU2003297844A1 (en) | Methods for reducing latency of a call set up | |
| HK1082173A1 (en) | Generalized metronome for modification of biorhythmic activity | |
| EP1777196A4 (en) | METHOD OF PURIFYING SILICON AND PURIFIED SILICON USING THE SAME | |
| SI1590061T1 (sl) | Metoda za äśiĺ äśenje alfa-1-antitripsina | |
| IL195370A0 (en) | A crystallization method for purification of calcipotriene | |
| HUP0302444A2 (hu) | Eljárás nitrogéntartalmú heterociklusos vegyületek monometilezésére | |
| AU2003215781A8 (en) | Method for production of phytoalexins | |
| PL376604A1 (pl) | Polimorfy chlorowodorku bicifadyny | |
| GB0209222D0 (en) | Purification process | |
| IL166592A0 (en) | Novel crystalline forms of gatifloxacin | |
| IL165115A0 (en) | Novel crystalline forms of gatifloxacin | |
| EP1512783A4 (en) | KNITTING METHOD | |
| TWI347932B (en) | Producing method of purified 2-cyanoacrylates | |
| AU2003286456A1 (en) | Method of purification of carbon dioxide | |
| GB0216531D0 (en) | Method of synthesis of carbon nanomaterials | |
| GB0224049D0 (en) | Removal of nitrogen compounds | |
| IL165690A0 (en) | Novel crystalline forms of gatifloxacin | |
| PL353509A1 (en) | Method of purification of 5-aminolevulline acid hydrochloride | |
| AU2003258982A8 (en) | Methods of inhibiting pin1-associated states using a fredericamycin a compound | |
| EP1511474A4 (en) | Methods of Treatment | |
| AU2003270107A1 (en) | Purification method for fredericamycin a | |
| GB0228795D0 (en) | Improvement to a device for correction of distortion | |
| TWI366564B (en) | Novel crude and crystalline forms of lercanidipine hydrochloride |